- NurExone (NRX) signed a Material Transfer Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
- The research will use the materials to evaluate compositions and methods to enhance the cellular uptake of particles and organelles by small molecules
- NurExone will have an option to receive an exclusive license to the jointly owned results and related intellectual property that may arise from the research
- NurExone develops biologically-guided ExoTherapy to deliver, non-invasively, to patients who has suffered traumatic spinal cord injuries
- NurExone Biologic Inc. (NRX) is down 5.00 per cent, trading at C$0.38 per share at 4:02 pm ET
NurExone (NRX) signed a Material Transfer Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Yissum is the wholly-owned subsidiary and technology transfer company of the Hebrew University of Jerusalem.
The agreement relates to transferring certain biological, chemical, and other tangible materials to Yissum for use by Prof. Tal Burstyn-Cohen and her team at the Hebrew University. Prof Burstyn-Cohen is an experienced researcher and leader of the Burstyn-Cohen Lab. The lab researches molecular and cellular mechanisms that underlie tissue homeostasis in health.
The research will use the materials to evaluate compositions and methods to enhance small molecules’ cellular uptake of particles and organelles. Prof. Burstyn-Cohen’s work will involve coating exosomes with a specialized molecule and assessing the uptake of the coated exosomes in an inflamed brain mouse model.
NurExone will have an option to receive an exclusive license to the jointly owned results and related intellectual property that may arise from the research.
Dr. Lior Shaltiel, CEO of NurExone, commented on the news.
“As a pioneer of ExoTherapy, NurExone’s goal is to establish leadership in the field of human mesenchymal-derived exosome production and loading of therapeutic molecules into exosomes. To advance the science, awareness and commercialization of ExoTherapy, we intend to facilitate cutting-edge exosome-based research at leading universities. We look forward to cooperating with Prof. Burstyn Cohen to assess the feasibility of her innovations.”
NurExone develops biologically-guided ExoTherapy to deliver, non-invasively, to patients who has suffered traumatic spinal cord injuries.
NurExone Biologic Inc. (NRX) is down 5.00 per cent, trading at C$0.38 per share at 4:02 pm ET.
